Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease.
Clavio M, Miglino M, Spriano M, Pietrasanta D, Vallebella E, Celesti L, Canepa L, Pierri I, Cavaliere M, Ballerini F, Beltrami G, Rossi E, Vimercati R, Bruni R, Congiu M, Nati S, Damasio E, Santini G, Gobbi M. Clavio M, et al. Among authors: gobbi m. Eur J Haematol. 1998 Sep;61(3):197-203. doi: 10.1111/j.1600-0609.1998.tb01084.x. Eur J Haematol. 1998. PMID: 9753416
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
Guolo F, Di Grazia C, Minetto P, Raiola AM, Clavio M, Miglino M, Tedone E, Contini P, Mangerini R, Kunkl A, Colombo N, Pugliese G, Carminati E, Marcolin R, Passannante M, Bagnasco S, Galaverna F, Lamparelli T, Ballerini F, Cagnetta A, Cea M, Gobbi M, Bacigalupo A, Lemoli RM, Angelucci E. Guolo F, et al. Among authors: gobbi m. Eur J Haematol. 2021 Nov;107(5):573-582. doi: 10.1111/ejh.13694. Epub 2021 Aug 12. Eur J Haematol. 2021. PMID: 34297437
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pierri I, Canepa L, Miglino M, Balleari E, Masoudi B, Damasio E, Ghio R, Sessarego M, Gobbi M. Clavio M, et al. Among authors: gobbi m. Leuk Lymphoma. 2001 Jan;40(3-4):305-13. doi: 10.3109/10428190109057929. Leuk Lymphoma. 2001. PMID: 11426552 Clinical Trial.
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.
Clavio M, Vignolo L, Albarello A, Varaldo R, Pierri I, Catania G, Balocco M, Michelis G, Miglino M, Manna A, Balleari E, Carella AM, Sessarego M, Van Lint MT, Bacigalupo A, Gobbi M. Clavio M, et al. Among authors: gobbi m. Br J Haematol. 2007 Jul;138(2):186-95. doi: 10.1111/j.1365-2141.2007.06646.x. Br J Haematol. 2007. PMID: 17593025 Free article. Clinical Trial.
757 results